Custom Epidemiology Case Studies

A leading global pharmaceutical company sought to quantify the market opportunity for a prophylactic treatment aimed at preventing recurrent anaphylaxis. The assessment needed to span five key markets — the USA, France, Germany, the UK, and Japan — and evaluate multiple market access scenarios based on combinations of anaphylactic trigger type, patient age group, and recurrence history.

Partnering with real‑world evidence (RWE) data providers and a specialist pharma consulting organization, Epivantage identified high‑quality datasets across several countries, including medical and pharmacy claims (US, Germany) and emergency room admission datasets (US, UK). Epivantage developed tailored study protocols for each dataset to estimate the incidence of anaphylaxis and the likelihood of recurrence.

Using insights from these RWD studies — combined with findings from a physician survey and a systematic review of published literature — Epivantage built a dynamic, interactive forecast model in Microsoft Excel, supported by a comprehensive study report.

The model enabled users to size the market opportunity across a wide range of access scenarios in each country and to profile the eligible patient population with precision. Equipped with this evidence, the client gained clearer direction on optimal future trial designs and regulatory submission strategies.